The agreements provide exclusive distribution rights for Elevess in each of these markets.
Elevess is an injectable filler that reduces the appearance of lines and wrinkles on the face, and was the first hyaluronic acid-based dermal filler approved by the FDA to incorporate the anesthetic lidocaine to improve patient comfort.
Charles Sherwood, president and CEO of Anika, said: “Since its introduction in August, 2008 the worldwide market interest in Elevess has been intense. We are excited to partner with these new distributors in Asia and Latin America. Each of these new partners is a leader in the dermatology field in their respective countries and we look forward to their success with Elevess.”